Top-News
Pharmazeutika USA

Jaguar Health Inc. News

Aktie
WKN:  A3D37R ISIN:  US47010C7065 US-Symbol:  JAGX
0,1317 €
-0,0211 €
-13,81%
20:52:12 Uhr
Handeln Depot/Watchlist
Aktienanzahl *
50,76 Mio.
Marktkapitalisierung *
7,88 Mio. €
Streubesitz
-
Index-Zugehörigkeit
-
IR-Website
zur Website
*Stand: 24.01.2024

Jaguar Health Inc. News

20.01.23 - PR Newswire
Thinking about buying stock in Salarius Pharmaceuticals, Appharvest, Ally Financial, Jaguar Health, or IONQ?
Thinking about buying stock in Salarius Pharmaceuticals, Appharvest, Ally Financial, Jaguar Health, or IONQ? PR Newswire
11.01.23 - PR Newswire
Thinking about buying stock in Jaguar Health, Avaya, Marathon Digital, Lucid, or Tonix Pharmaceuticals?
Thinking about buying stock in Jaguar Health, Avaya, Marathon Digital, Lucid, or Tonix Pharmaceuticals? PR Newswire
10.01.23 - PR Newswire
Thinking about buying stock in Prenetics Global, Bed Bath & Beyond, Jaguar Health, Warner Bros Discovery, or Sidus Space?
Thinking about buying stock in Prenetics Global, Bed Bath & Beyond, Jaguar Health, Warner Bros Discovery, or Sidus Space? PR Newswire
22.09.22 - ACCESSWIRE
Jaguar Health to Present at Lytham Partners Fall 2022 Investor Conference on September 28th and at Ladenburg Thalmann 2022 Healthcare Conference on September 29th
Jaguar CEO Lisa Conte Will Also Participate in an Orphan Drug Panel Presentation on September 28th During the Lytham Partners Fall 2022 Investor Conference
30.08.22 - ACCESSWIRE
Jaguar Health Announces Submission of Investigational New Drug (IND) Application to FDA for Drug Candidate for the Symptomatic Relief of Diarrhea from Cholera
Jaguar is concentrating financial and management resources on two near-term late-​stage clinical events
25.08.22 - ACCESSWIRE
Jaguar Health Secures Additional Capital Through Sale of Royalty Rights Related to Future Crofelemer and Lechlemer Revenue Stream
Transaction proceeds will be allocated to support the company's ongoing OnTarget pivotal Phase 3 clinical trial of crofelemer for prophylaxis of diarrhea in adults receiving targeted ...
23.08.22 - ACCESSWIRE
Jaguar Health Announces that Orphan Drug Designation Application Submitted to the FDA for Crofelemer for a Severe Congenital Diarrheal Disorder (CDD) Has Been Accepted for Review
Microvillus Inclusion Disease (MVID), a CDD, Is a Life-​Threatening and Rare Autosomal Recessive Disease That Affects Newborns and Children and Leads to Significant Morbidity ...
22.08.22 - ACCESSWIRE
Jaguar Health Provides Company Updates and Reports 2022 Second Quarter Financials
Prescription product net revenue of $2.9 million in Q2 2022 increased approximately 12.0% Quarter over Quarter, over Q1 2022; and increased approximately 641% Year over Year, ...
19.08.22 - ACCESSWIRE
Jaguar Health Receives Additional 180-day Grace Period to Regain Compliance with Nasdaq's Bid Price Rule
SAN FRANCISCO, CA / ACCESSWIRE / August 19, 2022 / Jaguar Health, Inc. (NASDAQ:JAGX) ("Jaguar" or the "Company") today announced that on August 18, 2022 the Company ...
17.08.22 - ACCESSWIRE
Jaguar Health to Host Investor Webcast Monday, August 22nd at 8:30 AM Eastern Time Regarding Q2 2022 Financials & Corporate Updates
Click here to register for webcast
10.08.22 - ACCESSWIRE
Gallup Survey Estimates Nearly 30 Million U.S. Dog Owners Have Experienced Canine Cancer, with Many Saying it Negatively Impacted Their Own Quality of Life
The emotional toll canine cancer takes on dog owners demonstrates the need for the Canine Cancer Care Index.
09.08.22 - ACCESSWIRE
Jaguar Health Announces Issuance of U.S. Patent 11,389,424, a Methods and Compositions Patent for Treating Chemotherapy-Induced Diarrhea
New patent bolsters intellectual property protection for the company's core target indication for crofelemer
05.08.22 - ACCESSWIRE
Jaguar Health Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
SAN FRANCISCO, CA / ACCESSWIRE / August 5, 2022 / Jaguar Health, Inc. (NASDAQ:JAGX) ("Jaguar" or the "Company") today announced that, effective August 5, 2022, the ...
05.07.22 - ACCESSWIRE
Jaguar Health Appoints Senior Healthcare and Investment Executive Dr. Anula Jayasuriya to Board of Directors and Forms Business Development Advisory Committee to Assess Opportunities for Alliances, Mergers, and Acquisitions
Greg Divis departs from Jaguar's Board of Directors; Experienced business development executive Rachel Zolot Schwartz chairs new committee
01.07.22 - ACCESSWIRE
Jaguar Health Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
SAN FRANCISCO, CA / ACCESSWIRE / July 1, 2022 / Jaguar Health, Inc. (NASDAQ:JAGX) ("Jaguar" or the "Company") today announced that, effective June 27, 2022, the Company ...
29.06.22 - ACCESSWIRE
Jaguar Health Enters Exclusive Crofelemer License and Commercialization Agreement with SynWorld Technologies for Canalevia for Treatment of Diarrhea in Dogs in China
License fees of $5.0 million, and up to $5.0 million in unregistered equity infusion, over next 24 months
24.06.22 - PR Newswire
Thinking about buying stock in Blue Hat Interactive, Vroom, Revlon, Roblox, or Jaguar Health?
Thinking about buying stock in Blue Hat Interactive, Vroom, Revlon, Roblox, or Jaguar Health? PR Newswire
22.06.22 - ACCESSWIRE
Jaguar Health Announces Online Availability of a Presentation on Short Bowel Syndrome (SBS) by Dr. Mohamad Miqdady at Elite Ped-GI Congress in Abu Dhabi
SAN FRANCISCO, CA / ACCESSWIRE / June 22, 2022 / Jaguar Health, Inc. (NASDAQ:JAGX) today announced that a presentation by Dr. Mohamad Miqdady on short bowel syndrome ...
21.06.22 - ACCESSWIRE
Jaguar Animal Health Exhibiting at the June 23-25 American College of Veterinary Internal Medicine (ACVIM) Forum as Part of Ongoing Commercial Launch Activities for Canalevia-CA1
Canalevia ® -CA1, which received conditional approval from the FDA on December 21, 2021, is the first and only treatment for chemotherapy-​induced diarrhea (CID) in dogs to ...
13.06.22 - ACCESSWIRE
Jaguar Health Announces Publication of Onco'Zine Article Underscoring the Importance of Controlling Diarrhea in Cancer Patients
Diarrhea is also a prevalent side effect in dogs undergoing cancer treatment; managing diarrhea can be important to maintain successful cancer treatment in both humans and dogs

Newssuche

Videos

17.05.24 -4,89%
Technical Trading: Gold Long-​Chance
Gold Long Typ: Turbo Open End WKN: VD1G7Y Hebel: 10 Laufzeit: OpenEnd Einstieg: Market ... Mehr »